Company appointed to project manage Oriel development at Moorfields Eye Hospital
AECOM has been appointed to provide project management services for Moorfields Eye Hospital and the UCL Institute of Ophthalmology to deliver Oriel – a new world-class eye health facility in King’s Cross.
Oriel will bring together leading eyecare services, ground-breaking research, and world-leading education in ophthalmology on one site.
The proposal is a partnership between Moorfields Eye Hospital, the UCL Institute of Ophthalmology, and Moorfields Eye Charity, which would see Moorfields Eye Hospital move its City Road services to the St Pancras Hospital site in Camden, where a new integrated facility housing the three partners will be built.
Richard Tunstall, director and project management lead for healthcare at AECOM, said: “We are delighted to be given the opportunity to work with Moorfields and UCL to deliver such an exciting and significant project.
“Our team of specialist healthcare project managers has extensive experience in the delivery of large, complex healthcare and research facilities such as Oriel.
“And this new commission will not only allow us to be part of delivering a world-class facility; but will also give us the chance to create a lasting legacy for Moorfields and the institute.”
Kieran McDaid, director of major projects for capital and estates at Moorfields, added: “As the Oriel project matures from its initial conceptual design through to delivery phase, we welcome the addition of AECOM’s experienced project management resource to the team.”
In 2019, the AECOM-led team and its partners, Penoyre & Prasad and White Arkitekter, won the RIBA design competition to provide all architectural design and related services for the project.
AECOM is acting as lead designer and providing civil, structural and building services engineering, as well as other specialist consultancy services.
Final approval on the scheme will be subject to approval of the full business case, which is expected to be put forward for review and approval later this year.